137419-24-0Relevant articles and documents
Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2
Chen, Xiaoqi,Mihalic, Jeff,Fan, Pingchen,Liang, Lingming,Lindstrom, Michelle,Wong, Sylvia,Ye, Qiuping,Fu, Ying,Jaen, Juan,Chen, Jin-Long,Dai, Kang,Li, Leping
, p. 363 - 366 (2012)
A series of spiropiperidine carbazoles were synthesized and evaluated as MCHR2 antagonists using a FLIPR assay. The pharmacokinetic properties of selected compounds have also been studied. This effort led to the discovery of potent and specific MCHR2 antagonists. Compound 38 demonstrated good pharmacokinetic properties across rat, beagle dog and rhesus monkey and had a favorable selectivity profile against a number of other receptors. These MCHR2 antagonists are considered appropriate tool compounds for study of the function of MCHR2 in vivo.
Novel heterocyclic derivative capable of being used as SHP2 inhibitor
-
Paragraph 0396-0399, (2019/08/30)
The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.
Compound as potassium channel modulator
-
Paragraph 1093; 1095; 1096; 1097, (2018/07/30)
The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.